Key Points
- HealthEquity EVP Michael Henry Fiore sold 3,142 shares on May 29 at an average price of $95, totaling about $298,490. The sale was made under a pre-arranged Rule 10b5-1 trading plan, and he still owned 59,113 shares afterward.
- HealthEquity recently beat quarterly earnings expectations, reporting EPS of $1.24 versus the $1.11 estimate and revenue of $354.64 million versus $352.02 million expected. Revenue rose 7.2% from a year earlier.
- Despite the insider sale, analysts remain largely constructive on the stock, with an overall Moderate Buy rating and an average price target of $111.53. Shares were down about 2.5% and opened at $88.34.
HealthEquity, Inc. (NASDAQ:HQY - Get Free Report) EVP Michael Henry Fiore sold 3,142 shares of the firm's stock in a transaction on Friday, May 29th. The shares were sold at an average price of $95.00, for a total transaction of $298,490.00. Following the sale, the executive vice president owned 59,113 shares in the company, valued at $5,615,735. The trade was a 5.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
HealthEquity Stock Down 2.5%
Shares of HQY stock opened at $88.34 on Wednesday. The company has a market capitalization of $7.39 billion, a price-to-earnings ratio of 33.09, a PEG ratio of 1.55 and a beta of 0.21. HealthEquity, Inc. has a one year low of $72.76 and a one year high of $116.65. The company's fifty day moving average price is $83.63 and its 200-day moving average price is $86.61. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.44 and a quick ratio of 3.44.
HealthEquity (NASDAQ:HQY - Get Free Report) last announced its quarterly earnings data on Thursday, May 28th. The company reported $1.24 EPS for the quarter, beating the consensus estimate of $1.11 by $0.13. The firm had revenue of $354.64 million for the quarter, compared to the consensus estimate of $352.02 million. HealthEquity had a net margin of 17.25% and a return on equity of 14.75%. HealthEquity's revenue was up 7.2% compared to the same quarter last year. HealthEquity has set its FY 2027 guidance at 2.880-2.950 EPS. Sell-side analysts expect that HealthEquity, Inc. will post 3.84 EPS for the current fiscal year.
Hedge Funds Weigh In On HealthEquity
Institutional investors and hedge funds have recently made changes to their positions in the business. Acumen Wealth Advisors LLC purchased a new position in shares of HealthEquity in the 4th quarter worth $27,000. Caitong International Asset Management Co. Ltd grew its stake in shares of HealthEquity by 1,723.5% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 310 shares of the company's stock worth $28,000 after buying an additional 293 shares in the last quarter. Aster Capital Management DIFC Ltd purchased a new position in shares of HealthEquity in the 4th quarter worth $28,000. Leonteq Securities AG grew its stake in shares of HealthEquity by 159.9% in the 1st quarter. Leonteq Securities AG now owns 382 shares of the company's stock worth $32,000 after buying an additional 235 shares in the last quarter. Finally, Axiom Investment Management LLC purchased a new position in shares of HealthEquity in the 1st quarter worth $33,000. 99.55% of the stock is owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
A number of analysts have issued reports on HQY shares. Barrington Research reiterated an "outperform" rating and issued a $110.00 price target on shares of HealthEquity in a report on Friday, May 22nd. Deutsche Bank Aktiengesellschaft lifted their price target on shares of HealthEquity from $120.00 to $128.00 and gave the company a "buy" rating in a report on Thursday, March 19th. Citigroup reiterated a "market outperform" rating on shares of HealthEquity in a report on Monday. BTIG Research reduced their price target on shares of HealthEquity from $130.00 to $110.00 and set a "buy" rating on the stock in a report on Tuesday, February 17th. Finally, JPMorgan Chase & Co. reduced their price target on shares of HealthEquity from $129.00 to $123.00 and set an "overweight" rating on the stock in a report on Wednesday, March 18th. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $111.53.
Check Out Our Latest Report on HQY
HealthEquity Company Profile
(
Get Free Report)
HealthEquity, Inc (NASDAQ: HQY) is a leading administrator of consumer-directed health accounts and related benefit solutions in the United States. Founded in 2002 and headquartered in Draper, Utah, the company specializes in health savings accounts (HSAs) and offers complementary services such as flexible spending accounts (FSAs), health reimbursement arrangements (HRAs), COBRA administration and commuter benefits. Through its technology-driven platform, HealthEquity enables employers, health plans and individuals to streamline account management, improve cost transparency and encourage more informed healthcare spending.
Serving millions of members across all 50 states, HealthEquity leverages an open-architecture ecosystem that integrates with health plans, payroll providers and financial institutions.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
